Medipixel - Series B round

One of our portfolio companies, Medipixel, an AI company in the cardiovascular interventional field, has completed a series B round of 13 million USD. (Currently, only Korean media released a related article)

Unfortunately, as of now, our active fund is focused on climate and environmental sectors, so we were unable to make a follow-on investment. However, we would like to thank the new investors (Premier Partners, Company K Partners, IMM Investment, IBK) and the existing investors (Quad Asset Management, Daily Partners) who participated in this round. We would also like to commend CEO Andy Song for completing this significant Series B round in these difficult times.

The digital healthcare and AI healthcare fields are areas that offer unlimited possibilities and imagination, and are directly linked to human health, so they give many people hope and excitement, and therefore various items are planned, and many startups come out. However, very few companies are realizing these dreams. The first barrier in this challenge is FDA approval, and the second barrier is designing achievable and scalable business models and commercialization that can generate sizable revenue. In this sense, receiving both kFDA and FDA approval for their first product, the cardiovascular diagnostic assistance solution Medipixel XA in March (news article), is a really great achievement, and now it is also on the verge of generating significant revenue through their commercial model.

We are sincerely grateful for all the efforts made by the members of Medipixel who are working hard every day to realize that difficult dream of automating the analysis and treatment of cardiovascular diseases!